Genmab A/S (OTCMKTS:GNMSF – Get Free Report) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $296.91 and traded as low as $274.16. Genmab A/S shares last traded at $278.34, with a volume of 810 shares trading hands.
Genmab A/S Trading Down 2.0 %
The company has a market capitalization of $18.20 billion, a price-to-earnings ratio of 23.04 and a beta of 1.05. The firm has a 50-day simple moving average of $291.74 and a two-hundred day simple moving average of $296.91.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last posted its earnings results on Wednesday, February 14th. The company reported $3.63 earnings per share (EPS) for the quarter. Genmab A/S had a net margin of 30.74% and a return on equity of 20.80%. The firm had revenue of $675.29 million during the quarter.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
See Also
- Five stocks we like better than Genmab A/S
- What is the S&P/TSX Index?
- Lucid’s Stock Price is Still in Reverse: New Lows Are Coming
- What is MarketRank™? How to Use it
- Generac Powers Ahead on the Electrification Mega-Trend
- What is the S&P 500 and How It is Distinct from Other Indexes
- PulteGroup Wins and Wins More on Interest Rate Cuts
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
